Present initial Phase 1b/2 data for Myelofibrosis Anemia
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 9 Jun 2023
- Due
- 31 Dec 2023
- Delivered
- December 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initial data expected by year-end 2023”
What we found
Evidence strength A What the grades mean
The company presented initial interim data from the Phase 1b/2 clinical trial for anemia of myelofibrosis at the American Society of Hematology annual meeting in December 2023, meeting the year-end deadline.
-
A Disc Medicine, Inc. 10-K filed 2024-03-21
“Interim data from this trial was presented at the American Society of Hematology annual meeting in December 2023.” ✓ confirmed on the page
-
A Disc Medicine, Inc. 8-K filed 2024-03-21
“Presented positive, initial data from ongoing phase 1b/2 clinical study in MF patients with severe anemia at ASH 2023” ✓ confirmed on the page
Market reaction: the shares moved -10.3% against the S&P 500 over the three sessions around the disclosure (20 Mar 2024 to 25 Mar 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +731 days
- 2 versions
-
Version 1 · original · stated 9 Jun 2023
Deadline 31 Dec 2023 (“year-end 2023”) · wording expected
-
Version 2 · stated 6 Nov 2025
Deadline 31 Dec 2025 (“December”)
“Initial data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) to be presented at the American Society of Hematology (ASH) conference in December”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- Initial Phase 1b/2 data for Myelofibrosis Anemia
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Disc Medicine, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-IRON-002144 · Corrections policy